Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis

Aim： To explore the potent inhibitor from one of the Traditional Chinese medicine （TCM）, Epimedium sagittatum. Methods： We predicted the potent compound, ESO3b, de novo evolution from the four Epimedium sagittatum components were verified by molecular docking, pharmacophore analysis, and analysis of...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmacologica Sinica 2009-08, Vol.30 (8), p.1186-1194
Main Authors: Chen, Chien-yu, Chang, Yea-huey, Bau, Da-tian, Huang, Hung-jin, Tsai, Fuu-jen, Tsai, Chang-hai, Chen, Calvin Yu-chian
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Cyclic Nucleotide Phosphodiesterases, Type 5 - chemistry
Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism
Drugs, Chinese Herbal - chemistry
Drugs, Chinese Herbal - pharmacology
Epimedium - chemistry
Erectile Dysfunction - drug therapy
Humans
Immunology
Internal Medicine
Male
Medical Microbiology
Models, Molecular
Molecular Structure
Original
original-article
Pharmacology/Toxicology
Phosphodiesterase 5 Inhibitors
Protein Binding
Quantitative Structure-Activity Relationship
Vaccine
传统中药
分子对接
多元线性回归
抑制剂
磷酸二酯酶
结合位点
药效分析
虚拟筛选
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim： To explore the potent inhibitor from one of the Traditional Chinese medicine （TCM）, Epimedium sagittatum. Methods： We predicted the potent compound, ESO3b, de novo evolution from the four Epimedium sagittatum components were verified by molecular docking, pharmacophore analysis, and analysis of quantitative structure-activity relationship （QSAR） model, which was constructed by multiple linear regression. Results： ESO3b was chosen to undergo drug modification via de novo evolution. By analyzing the pharmacophore features, we found that the hydrophobic core in the binding site and the hydrogen bond generated at Asn663 played key roles in designing PDE5 inhibitors. ESO3b generated 49 diversities （Evo01-49）. Evo48 had high activity in prediction. Although the value of prediction was overestimated, Evo48 was suggested as the potent lead. Conclusion： In this study, we showed that the hydrophobic core in the binding site and hydrogen bond production on Asn663 played key roles to design PDE5 inhibitors. From several require validation analysis, Evo48 was suggested to be a potent inhibitor.
ISSN:1671-4083
1745-7254
DOI:10.1038/aps.2009.100